Clinical trials: Attention Control

Parkinson's Disease

Levodopa Concentration Profile With Stalevo 75/125 mg

• Completed
• Age: 18 to 70 years
• Phase 1

The purpose of this study is to confirm that the dose levels and dosing frequency utilising the new Stalevo strengths would result into more stable levodopa plasma levels.

Trial name

NEWSTA (NCT01070628)

Testing

Stalevo (levodopa/ carbidopa/ entacapone), Sinemet (levodopa/carbidopa)

Where

Finland

Volunteers

20 people, healthy volunteers welcome

Sponsor

Orion Corporation, Orion Pharma